Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Vivos Therapeutics Inc (NASDAQ:VVOS) shares are trading lower by 26.1% to $3.05 during Thursday’s session after the company announced a $4.3 million registered offering of 1.36 million shares of common stock at $3.
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent trading after closing at $4.
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults),
Vivos Therapeutics Offers Of 1.363 Mln Shares At $3.15/share, Pre-Market Stock Down
Vivos Therapeutics, Inc. (VVOS), a medical device and technology company, announced on Thursday that it has inked a deal with
Vivos surges on FDA nod for pediatric sleep apnea device
Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep ...
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...
Benzinga.com1d
Vivos Therapeutics (NASDAQ:VVOS) Stock, Short Interest Report
Short interest in Vivos Therapeutics Inc (NASDAQ:VVOS) decreased during the last reporting period, falling from 58.82K to 56.53K. This put 2.28% of the company's publicly available shares short.
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep ...
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing ...
Investornewsbreaks Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance For Pediatric Treatment Of Sleep Apnea, Snoring
Vivos Therapeutics (NASDAQ: VVOS) , a leading medical-device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related ...
FDA Approval Sends Shares of this Healthcare Company Higher
What a session it was for a certain Colorado-based %Healthcare company after it was announced that it received the US Food ...
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000
U.S. stocks traded higher this morning, with the Nasdaq Composite surging more than 400 points on Thursday. Following the ...